Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $59.00
Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective boosted by investment analysts at Barclays from $57.00 to $59.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target indicates a potential upside of 84.32% from the company’s current price. […]
Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective boosted by investment analysts at Barclays from $57.00 to $59.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target indicates a potential upside of 84.32% from the company’s current price. […]
